BACKGROUND: The histone-modifying enzymes histone deacetylase (HDAC) and histone acetyltransferase (HAT) control gene transcriptional activation and repression in human malignancies. AIMS: To analyse the expression of HDAC/HAT-associated molecules such as HDAC1, CREB-binding protein (CBP) and p300 in human colorectal carcinomas, and investigate the relationship between their expression levels and clinicopathological parameters. METHODS: Expression levels of HDAC1, CBP, and p300 in human colorectal cancer were investigated by immunohistochemistry. In situ hybridisation (ISH) and reverse transcription (RT)-PCR analyses were also carried out to confirm mRNA expression levels of these genes. Immunoreactivity was evaluated semi-quantitatively using a staining index (SI). The relationships between the SIs and clinicopathological findings were analysed and survival curves were calculated using the Kaplan-Meier method and log-rank tests. RESULTS: The mean SIs for HDAC1, CBP, and p300 in this series of tumours were much higher than those in normal colonic mucosa. The presence of HDAC1 and CBP mRNAs on colorectal carcinoma cells as well as normal epithelial cells was confirmed by ISH analysis. A marked increase in p300 mRNA levels was detected in a majority of cases by RT-PCR. Among the patients with colorectal cancer, overexpression of p300 (SI>11.9) correlated with a poor prognosis, whereas high CBP expression levels (SI>16.6) indicated long-term survival. CONCLUSION: Results showed the up-regulation of these three histone-modifying molecules in this series of colorectal cancers and suggested that monitoring of CBP and p300 may assist prediction of the prognosis in patients with colorectal adenocarcinoma.
BACKGROUND: The histone-modifying enzymes histone deacetylase (HDAC) and histone acetyltransferase (HAT) control gene transcriptional activation and repression in humanmalignancies. AIMS: To analyse the expression of HDAC/HAT-associated molecules such as HDAC1, CREB-binding protein (CBP) and p300 in humancolorectal carcinomas, and investigate the relationship between their expression levels and clinicopathological parameters. METHODS: Expression levels of HDAC1, CBP, and p300 in humancolorectal cancer were investigated by immunohistochemistry. In situ hybridisation (ISH) and reverse transcription (RT)-PCR analyses were also carried out to confirm mRNA expression levels of these genes. Immunoreactivity was evaluated semi-quantitatively using a staining index (SI). The relationships between the SIs and clinicopathological findings were analysed and survival curves were calculated using the Kaplan-Meier method and log-rank tests. RESULTS: The mean SIs for HDAC1, CBP, and p300 in this series of tumours were much higher than those in normal colonic mucosa. The presence of HDAC1 and CBP mRNAs on colorectal carcinoma cells as well as normal epithelial cells was confirmed by ISH analysis. A marked increase in p300 mRNA levels was detected in a majority of cases by RT-PCR. Among the patients with colorectal cancer, overexpression of p300 (SI>11.9) correlated with a poor prognosis, whereas high CBP expression levels (SI>16.6) indicated long-term survival. CONCLUSION: Results showed the up-regulation of these three histone-modifying molecules in this series of colorectal cancers and suggested that monitoring of CBP and p300 may assist prediction of the prognosis in patients with colorectal adenocarcinoma.
Authors: T Suzuki; H Yokozaki; H Kuniyasu; K Hayashi; K Naka; S Ono; T Ishikawa; E Tahara; W Yasui Journal: Int J Cancer Date: 2000-12-15 Impact factor: 7.396
Authors: T Murata; R Kurokawa; A Krones; K Tatsumi; M Ishii; T Taki; M Masuno; H Ohashi; M Yanagisawa; M G Rosenfeld; C K Glass; Y Hayashi Journal: Hum Mol Genet Date: 2001-05-01 Impact factor: 6.150
Authors: L M Butler; D B Agus; H I Scher; B Higgins; A Rose; C Cordon-Cardo; H T Thaler; R A Rifkind; P A Marks; V M Richon Journal: Cancer Res Date: 2000-09-15 Impact factor: 12.701
Authors: M S Kim; H J Kwon; Y M Lee; J H Baek; J E Jang; S W Lee; E J Moon; H S Kim; S K Lee; H Y Chung; C W Kim; K W Kim Journal: Nat Med Date: 2001-04 Impact factor: 53.440
Authors: Jijun Hao; Ada Ao; Li Zhou; Clare K Murphy; Audrey Y Frist; Jessica J Keel; Curtis A Thorne; Kwangho Kim; Ethan Lee; Charles C Hong Journal: Cell Rep Date: 2013-09-05 Impact factor: 9.423
Authors: Annunziata Gloghini; Daniela Buglio; Noor M Khaskhely; Georgios Georgakis; Robert Z Orlowski; Sattva S Neelapu; Antonino Carbone; Anas Younes Journal: Br J Haematol Date: 2009-09-22 Impact factor: 6.998
Authors: Jennifer S Waby; Haridasan Chirakkal; ChenWei Yu; Gareth J Griffiths; Roderick S P Benson; Colin D Bingle; Bernard M Corfe Journal: Mol Cancer Date: 2010-10-15 Impact factor: 27.401
Authors: Junko Suzuki; Yunn-Yi Chen; Gary K Scott; Sandy Devries; Koei Chin; Christopher C Benz; Frederic M Waldman; E Shelley Hwang Journal: Clin Cancer Res Date: 2009-04-21 Impact factor: 12.531